Many antiphospholipid antibodies (aPL) are observed in patients with COVID-19, with most studies published to date including only one aPL measurement point—generally during the acute phase—without confirmation after at least three months, as defined by the laboratory criteria for antiphospholipid syndrome (5). This evidence concerns the gene FASLG and antiphospholipid syndrome.